Hybrigenics SA represents strong values and a distinct corporate philosophy. The company prides itself on innovation, commitment to scientific excellence, and dedication to improving human health. Hybrigenics SA emphasizes transparency, integrity, and accountability in all its operations. Through cutting-edge research and development, the company aims to create innovative therapies and diagnostic solutions for challenging diseases. With a focus on collaboration and partnerships, Hybrigenics SA strives to make a meaningful impact in the biotechnology and pharmaceutical industries. Overall, Hybrigenics SA stands for pushing boundaries, delivering quality, and pioneering advancements in the field of life sciences.

Hybrigenics SA is primarily present in France, with its headquarters located in Paris. As a biopharmaceutical company, Hybrigenics SA focuses on research and development in the field of oncology. With a strong presence in France, Hybrigenics SA conducts its operations and collaborates with various institutions, universities, and research centers within the country. Its commitment to advancing scientific knowledge and therapeutic solutions has established Hybrigenics SA as a prominent player in the French biotechnology industry.

Hybrigenics SA, a leading biopharmaceutical company, has achieved several significant milestones. One notable achievement is the successful completion of Phase II clinical trials for its innovative drug candidate, Inecalcitol, in patients with acute myeloid leukemia. Additionally, Hybrigenics SA has formed strategic partnerships with renowned pharmaceutical companies, facilitating the advancement of its drug development programs. The company's dedication to research and development is demonstrated by its numerous patent filings and scientific publications. Moreover, Hybrigenics SA's strong commitment to expanding its global reach is evident through the establishment of subsidiaries in the United States and the opening of international offices.

Hybrigenics SA is a French biopharmaceutical company with a rich history and background. Established in 1997, Hybrigenics focuses on identifying and developing innovative treatments for various diseases, particularly in the field of oncology. It has built expertise in protein interactions and developed the UniTrap technology for high-throughput yeast two-hybrid screenings. Over the years, the company has achieved significant milestones, including the discovery of inecalcitol, a potential therapeutic agent for acute myeloid leukemia (AML). Hybrigenics SA continues to advance research and development efforts, leveraging its scientific capabilities and collaborations to discover novel drug candidates and address unmet medical needs.

The main competitors of Hybrigenics SA in the market include pharmaceutical and biotechnology companies such as Genmab, Celgene Corporation, and Novartis AG.

Hybrigenics SA is primarily active in the biotechnology and pharmaceutical industries.

Hybrigenics SA is a biopharmaceutical company specializing in research and development of innovative cancer treatments. Their business model focuses on the discovery and development of targeted therapies, using a unique technology called "protein interactions," which enables the identification of novel therapeutic targets. By leveraging their expertise in protein sciences and oncology, Hybrigenics aims to advance the understanding of cancer biology and contribute to the development of effective and personalized cancer treatments. With a strong emphasis on scientific excellence, Hybrigenics is dedicated to discovering breakthrough therapies that can significantly impact the lives of cancer patients worldwide.

The P/E ratio cannot be calculated for Aton at the moment.

The P/S cannot be calculated for Aton currently.

The AlleAktien quality score for Aton is 1/10.

The revenue cannot currently be calculated for Aton.

The profit cannot currently be calculated for Aton.

Hybrigenics SA is a leading biotechnology company specialized in the discovery of innovative therapies for serious diseases such as cancer, neurodegenerative diseases, and infectious diseases. The company is based in Paris, France, and employs an international team of scientists working on the development and commercialization of new drugs. Hybrigenics' business model is based on three main areas: biopharmaceutical business, service business, and research and development program. The biopharmaceutical business of Hybrigenics includes the research and development of drugs against cancer and neurodegenerative diseases. The company uses its proprietary technology platform, UbiTrap®, to specifically identify proteins related to disease development. Based on these findings, the company develops novel therapies that aim to selectively target specific disease-relevant proteins. One product that has emerged from this business area is a drug against acute myeloid leukemia (AML) called Inecalcitol. It is currently in phase IIb of clinical trials and has shown promising results. Additionally, Hybrigenics is working on the development of therapies for Parkinson's and Alzheimer's by identifying and targeting protein aggregates in a similar manner. Hybrigenics' service business includes various types of contract research services. The company offers specialized protein research services to its customers based on the UbiTrap® technology platform. Customers can submit their own proteins, and the company identifies specific interaction partners or posttranslational modifications with high specificity and sensitivity. Hybrigenics also offers network analysis to identify and characterize protein interaction partners, gaining a better understanding of the complex signaling pathways and mechanisms that cause diseases. This service is in high demand in the pharmaceutical and biotechnology industry. Lastly, Hybrigenics conducts an extensive research and development program to develop new technologies and products that could complement its existing product range. This program focuses on identifying new molecular targets that have not been previously known and optimizing existing technologies. In summary, Hybrigenics' business model aims to utilize its proprietary technology platform to identify new target molecules and develop innovative therapies against cancer and neurodegenerative diseases. The company complements these activities with a wide range of services targeting pharmaceutical and biotech companies, including the identification of protein modifications and network analysis. With a strong focus on research and development, Hybrigenics is well positioned to further expand its portfolio of products and services in the future.

Aton pays a dividend of 0 EUR distributed over payouts per year.

The dividend cannot currently be calculated for Aton or the company does not pay out a dividend.

The ISIN of Aton is FR0004153930.

The WKN of Aton is A0M9ZU.

The ticker of Aton is ALTAO.PA.

Over the past 12 months, Aton paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aton is expected to pay a dividend of 0 EUR.

The current dividend yield of Aton is .

Aton pays a quarterly dividend. This is distributed in the months of .

Aton paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

Aton is assigned to the 'Health' sector.

To receive the latest dividend of Aton from 9/26/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.

The last dividend was paid out on 9/26/2024.

In the year 2023, Aton distributed 0 EUR as dividends.

The dividends of Aton are distributed in EUR.